A RABBIT VENOUS MODEL OF INFUSION INFILTRATION TO STUDY THE EFFECT OF A HYPEROSMOTIC SOLUTION

Similar documents
The relationship between the tip position of an indwelling venous catheter and the subcutaneous edema

Is Thrombus With Subcutaneous Edema Detected by Ultrasonography Related to Short Peripheral Catheter Failure?

Direct Intravenous (IV) Medication Administration Procedure

Intravenous Catheter Complications

IV Fluids Nursing B23 Objectives Serum Osmolality 275 to 295 Isotonic

External Ref: Andres, D.A., et al. Catheter Pinch-Off Syndrome: Recognition and Management.

STRATEGY OR RISK: THE USE OF MIDLINE CATHETERS. Timothy R. Spencer BH, RN, APN, VA- BC

IV Drug Delivery Systems used in Cancer Care

IV Fluids. Nursing B23. Objectives. Serum Osmolality

If viewing a printed copy of this policy, please note it could be expired. Got to to view current policies.

Value Life Lifecath Midli n e uide to Lifecath Midline rse s G u N A

Fundamentals of Flushing and Locking

Jo Kuehn, RN, MSN, CPHQ Jenell Westhoven, RN, BSN

LPN 8 Hour Didactic IV Education

Vascular access device selection & placement. Alisa Seangleulur, MD Anesthesiology Department, Faculty of Medicine, Thammasat University

A Primer on Central Venous Access: Peripherally-Inserted Central Catheters, Tunneled Catheters, and Subcutaneous Ports

PARENTERAL NUTRITION: VASCUAR ACCESS DEVICE SELECTION

TYPES AND USES OF VENOUS ACCESS DEVICES

Peripherally Inserted Central Catheter (PICC) Booklet

Appendix E: Overview of Vascular

Chapter 64 Administration of Injectable Medications

Successful IV Starts Revised February 2014

Overview of CVADs. Type of device commonly used. Dwell time Flushing requirement Associated complications. lumens

IV therapy. By: Susan Mberenga, RN, MSN. Copyright 2016, 2013, 2010, 2006, 2002 by Saunders, an imprint of Elsevier Inc.

Disclosure Statement. Learning Objectives. Background. Background. Background 4/18/2018

Parenteral Nutrition in the Hospitalized Patient: which VAD, which policies? Rob Dawson DNP, MSA, APRN, ACNP-BC, VA-BC USA

Navigating Vascular Access Issues

Complications of Central Vascular Access Devices

Emergency clamp should always be readily available in case of accidental catheter fracture

Introduction. Acute sodium overload produces renal tubulointerstitial inflammation in normal rats

Unit 11. Objectives. Indications for IV Therapy. Intravenous Access Devices & Common IV Fluids. 3 categories. Maintenance Replacement Restoration

Longitudinal Validation Study: Streptozotocin-Induced Diabetes as a Model of Diabetic Retinopathy in Brown Norway Rats

PACKAGE LEAFLET: INFORMATION FOR THE USER. Glucose Intravenous Infusion BP 10% w/v solution for infusion Glucose (as glucose monohydrate)

The Impact of Catheter Occlusion in Central Line Associated Bloodstream Infections M A R C H 15, 2017

NURSING PRACTICE GUIDELINES

Is it Necessary to Verify Blood Return in Monthly Port Flushes?

Complications Associated With IV Therapy

Central Venous Access Devices. Stephanie Cunningham Amy Waters

The Power of Purple* Polyurethane PICC. Patient Guide. Access Systems

If viewing a printed copy of this policy, please note it could be expired. Got to to view current policies.

Biovalve. A Guide to Peripheral IV Cannulation CANNULATION

CENTRAL VENOUS ACCESS DEVICES. BETHANY COLTON

Central Line Care and Management

THE CARE AND MAINTENANCE OF TOTALLY IMPLANTED VENOUS ACCESS DEVICES (PORTS)

Parenteral Products. By: Howida Kamal, Ph.D

IV Therapy January, 08 Tip of the Month

Portacath Insertion. Patient Information Leaflet

Advancing Lives and the Delivery of Health Care. The High-Flow Port Designed for Apheresis

Vaxcel Implantable Ports Valved and Non-Valved. A Patient s Guide

Chapter 16 IV Flow Rates. Name three reasons why you think a person may need fluid replacement, IV fluids.

Supplementary Figure 1 Detailed description of the MDP fabrication procedures

MODULE 2 THE LABORATORY RAT

Curraheen, Co. Cork. Guidelines on the Management and Care of Central Venous Access Devices

PRESCRIBING INFORMATION. Dextrose Injection USP. (Concentrated Dextrose for Intravenous Administration) 50% (500 mg/ml) Fluid and Nutrient Replenisher

High Flow Family. Short Term Dialysis Catheters. Dialysis

IMMUNOGLOBULIN REPLACEMENT THERAPY: ONE SIZE DOESN T FIT ALL

ARROW ENDURANCE. Extended Dwell Peripheral Catheter System. Rx only.

Taking the Lead in Vascular Access Improving Patient Outcomes

Fistula/Graft Protection. Leslie Dork Renal Medicine Associates

Additional Information S-55

Y s A P. n n. C o. e c. t o r s E R. e s. e l. e e d l I V. e d o s C l. vadsite The Transparent, Split Septum, Needleless Connector

PICC, port e trombosi cateterecorrelata: la prevenzione è legata alla tecnica di impianto!

Contrast-enhanced small bowel ultrasound in the assessment of the small bowel in patients with Crohn s Disease

In Vivo Histological Evaluation of a Novel YSGG Ablative Fractional Device for Cutaneous Remodeling

Ultrasound Guidance Needle Techniques

The incidence and cumulative risk of primary bloodstream and venous infections in 12,942 peripheral intravenous catheters in Australia

Upper Extremity Venous Duplex. Michigan Sonographers Society Fall Ultrasound Symposium October 15, 2016

Nuovi materiali per la prevenzione di infezione e trombosi: quali evidenze?!

Standard Operating Procedure

Comparative Biosciences Model of Monocrotaline-Induced Pulmonary Hypertension in Rats

Preserving sites and protecting veins

To you who will receive a T-Port PATIENT INFORMATION

Ultrasound for Vascular Access

Peripherally Inserted Central Catheter & Midline Placement with ECG Confirmation of Tip Placement

REVERSAL OF ILEOSTOMY. Patient information Leaflet

University of Canberra. This thesis is available in print format from the University of Canberra Library.

You have a what, inside you?

You have a what, inside you?

Peripheral Cannulation

Background & Indications Probe Selection

BioFlo PICC. with Endexo and PASV Valve Technology. Clinician Reference Tool

If viewing a printed copy of this policy, please note it could be expired. Got to to view current policies.

Vascular Access Care Plans: How Can a Care Plan Really Improve Care and Make Everyone s Job Easier?

Mary Lou Garey MSN EMT-P MedFlight of Ohio

Obesity and Liver Disease:Evaluation of Fatty Infiltration of the Liver. Using Ultrasonic Attenuation

Blood Culture Collection and Interpretation

Choosing the right access for long term parenteral nutrition: PICC lines or tunnelled catheters G. Goossens (BE)

reached, and then rotated with moderate pressure until the tip entered the PULMONARY FAT EMBOLISM FOLLOWING INFUSIONS VIA THE BONE MARROW1

Department Policy. Code: D:PC Entity: Fairview Pharmacy Services. Department: Fairview Home Infusion. Manual: Policy and Procedure Manual

Infusion Skills Competency Checklist To be used at annual skills fair or at any other time for IV Competency

10/28/2015. Disclaimer. Disclaimer

IR Central Venous Access [ ] Pre Procedure

X: Infusion Therapy. Saskatchewan Association of Licensed Practical Nurses, Competency Profile for LPNs, 3rd Ed. 201

** Medication exercises ** NICU Phase II

Patient guide: pfm Nit-Occlud PDA coil occlusion system. Catheter occlusion of. Patent Ductus Arteriosus. with the

Tissue Adhesive: A New Tool for the Vascular Access Toolbox. What s in your toolbox?

Totally indwelling venous access devices

ULCERS 1/12/ million diabetics in the US (2012) Reamputation Rate 26.7% at 1 year 48.3% at 3 years 60.7% at 5 years

Support Methods for Internal Shunt in Patients with Kidney Dysfunction

Developments in Ultrasonic Inspection II

Transcription:

A RABBIT VENOUS MODEL OF INFUSION INFILTRATION TO STUDY THE EFFECT OF A HYPEROSMOTIC SOLUTION Hidenori Tanabe 1,2, Naoto Takemura 2, Ryoko Murayama 1, Makoto Oe 3, Hiromi Sanada 4 1 Advanced Nursing Technology, the University of Tokyo 2 Terumo corporation 3 Global Nursing Research Center, the University of Tokyo 4 Department of Gerontological Nursing / Wound Care Management, the University of Tokyo The University of Tokyo

Conflict of interest Hidenori Tanabe is a collaborative researcher of the University of Tokyo and has been employed by TERUMO corporation (Tokyo, Japan). Naoto Takemura is also a research associate at TERUMO corporation. The other authors have been determined to have no conflict of interest. Funding This research was a joint project with Terumo corporation, conducted with sponsorship from this organization.

EVENTUAL GOAL We would like to suggest the most suitable routes for the administration of a hyperosmotic solution through animal studies. CVC MID PIVC

Insertion of PIVC OUR PREVIOUS STUDY An observational study in a university hospital (2014) The rate of catheter failure (CF) was reported to be 30%. Used ultrasonography (US) to better understand the causes of CF. (Takahashi et al. 2015) Removal Catheter Vein Noblus (Hitachi Aloka Medical) Linear-array transducer (5-18MHz)

OUR PREVIOUS STUDY We classified US images detected in the study into N=186 PIVC (145 subjects) four types of US features. A: No signs; 51 PIVCs Catheter (25.5%) B: Thrombus ; 48 PIVCs (24.0%) Vein We found no catheter dislocations in this study. Our results suggest that catheter failure could be D: Thrombus with subcutaneous C: Subcutaneous edema; 30 caused by other reasons than dislocation. edema; catheter 57 PIVCs (28.5%) PIVCs (15.0%) Figure 1. Typical US features (A-D) (Yabunaka et al. 2015) The mild echo spots in the vein show partial occlusion of the vein by thrombus. The area surrounding the vein with the PIVC tip appeared as an edema of the subcutaneous fat layer (circles). We could not evaluate 14 (7.0%) US images because of poor image quality.

OUR PREVIOUS STUDY Table 1. Rates of catheter failure (CF) with and without BFLUID Rates of CF N=200 Patients with BFLUID 66% (25/38) Patients without BFLUID 22% (35/162) CF was defined as accidentally removal of the catheter due to the signs, symptoms and insufficient dripping. BFLUID (845mOsm/L) has been commonly used in Japanese acute care hospitals for PPN in short time duration. Infusion Nurses Society (INS) recommends that Central Venous Access Device (CVAD) is preferred for continuous infusion of hypertonic solution (osmolarity > 900mOsm/L). (Policies and Procedures for Infusion Therapy, 2016)

SYMPTOMS ASSOCIATED WITH HYPERTONIC SOLUTION What is the main symptom of CF in patients who received hypertonic solution? Table 2. Rates of clinical presentation of CF in patients with BFLUID Clinical presentation Rates (n/n) Edema 64 % (16/25) Pain 60 % (15/25) Erythema 48 % (12/25) Palpable venous cord 24 % (6/25) Edema, which is the main symptom of CF, can be defined as infiltration based on the INS rating scale.

Vessel diameter OUR PREVIOUS STUDY To reveal any differences in mean diameter between veins with infiltration and those without infiltration, US was used. Short-axis sonographic image of a vein with inserted PIVC tip Noblus (Hitachi Aloka Medical) Liner-array transducer (5-18MHz) Table 3. Vessel diameter with and without infiltration in patients receiving BFLUID Infiltration Mean (SD), mm n=5 No-infiltration Mean (SD), mm n=6 Vessel diameter 1.3 (0.29) 2.6 (0.81).008 To clarify whatʼs happening in the vein, experimental studies using animal models are needed. p

HYPOTHESIS Infiltration can be caused by mechanical, physiologic, or pharmacologic factors. (Hadaway, 2007) Vesicant solutions can irritate the venous endothelium, allowing the solutions to escape from the gap of the vein into the surrounding tissue. (Pettit J, 1993) Our hypothesis Undemonstrated Hyperosmotic solution causes the loss of vascular endothelial cells, which leads to the passage of fluid (= edema defined as infiltration). Specific observation of venous endothelium is needed.

EXPERIMENTS MODEL Rabbit ear vein has usually been used for investigations of infusion complications. (Kuwahara T. 1998) Investigations were limited to morphological observations.

AIM To establish an animal model of infiltration induced by a hyperosmotic solution, a rabbit ear vein was administered with such a solution and observed specifically using immunostaining method.

METHOD Male Japanese white rabbit weighing from 2.5 to 3.5 kg was used. This study was approved by our Institutional Committee on the care and use of laboratory animals. Our facility (TERUMO corporation) has full accreditation by AAALAC International.

METHOD Hyperosmotic solution was administered via the rabbitʼs left ear vein and normal saline was infused via the rabbitʼs right ear vein using PIVCs (24G). Glucose:36% Osmolality rate:2250 mosm/l clip Rabbit ear vein Syringe pump (24ml/h) The total infusion duration was 1 hr; infusion comprised 10 cyclic infusions with 1-min infusion each, and the solution in the vessel was clipped by clamps for 5 mins.

METHOD After administering the solutions, ear vein tissues were sampled and fixed in 10% neutral buffered formalin. Cross-sections of the ear vein tissues, one from a 30mm region in front of catheter tip were trimmed, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (HE) and immunostaining with CD31 and α-sma antibody. Infiltration was defined as the presence of subcutaneous edema.

RESULTS (HE) Normal saline (right ear vein) Hyperosmotic solution (left ear vein) edema vein cartilage

RESULTS (HE) Hyperosmotic solution (left ear vein) Inflammatory cells Some inflammatory cells (arrows) were observed in the venous wall.

RESULTS (CD31) Normal saline (right ear vein) Hyperosmotic solution (left ear vein)

RESULTS (NORMAL SALINE) No damage to vascular endothelial cells (intact)

RESULTS (HYPERTONIC) Loss of vascular endothelial cells caused by hyperosmotic solution

RESULTS (SMA) Normal saline (right ear vein) Hyperosmotic solution (left ear vein) No damage to vascular smooth muscle infused by both normal saline and hyperosmotic solution

DISCUSSION According to the HE stained images, subcutaneous edema was observed in the tissue infused by hyperosmotic solution. There was no damage to vascular smooth muscle by hyperosmotic solution using α-sma antibody. On the other hand, the vein infused by hyperosmotic solution showed loss of vascular endothelial cells using CD31 antibody. This was the first study to show that infiltration (edema) was due to the loss of endothelial cells, not vascular smooth muscle, in veins infused by hyperosmotic solution

FUTURE PLAN The flow of the lower arm veins: 20-40 ml/min The vessel flow of the upper arm: 100-150 ml/min (Bard Access Systems. 2002) The increased blood flow can dilute a drug s osmolarity, reducing the risk of infiltration. Future studies should compare vessel damage between different blood-flow-veins using this animal model, in order to implement these results into human. vein VS. vein Small vein (20-40 ml/min) Large vein (100-150 ml/min)

VASCULAR ACCESS DEVICES Certified vascular nurses are not in Japan. Physicians are responsible of all VADs. Since 2002, Japanese nurses have been able to implement PIVC. Japan The Michigan Appropriateness Guide for Intravenous Catheters (MAGIC), 2015

FUTURE PLAN CVC MID PIVC The University of Tokyo Our research group will suggest safe administration routes through mechanism based studies.

CONCLUSION Conclusion Hyperosmotic solutions can lead to edema, defined as infiltration due to the loss of endothelial cells. This model can be useful in establishing safe administration routes and adequate PPN osmolality. Limitation It is still unclear whether the administered solution leaked from the vein, or whether tissue fluid increased in surrounding subcutaneous tissue due to inflammation reaction.